The shareholder vote on the Mentari merger is the critical near-term catalyst. If approved, the $490M private placement could resolve the cash and Nasdaq compliance issues. If the merger fails, InMed faces imminent cash depletion and potential delisting.
INM drugs
INM drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $1.75entry
- T+1 · 12d ago −24.51%α −20.11% · $1.32
- T+5 · 6d ago −11.09%α −10.17% · $1.56
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals reported Q1 FY2027 results with a net loss of $2.33M, cash burn reducing cash to $1.09M (runway into mid-November), and shareholders' equity turning negative at -$1.20M. The company is pursuing a merger with Mentari Therapeutics (shareholder vote Nov 4) and has a Nasdaq compliance plan accepted through March 2027.
Key Facts
- Net loss of $2,330,778 for Q1 FY2027 vs $1,726,899 in Q1 FY2026
- Cash and cash equivalents fell to $1,094,488 from $2,194,413 at June 30, 2026
- Shareholders' equity turned negative at -$1,199,396 vs $1,075,007 at June 30, 2026
- Cash runway expected only into mid-November 2026
- Nasdaq compliance plan accepted with deadline of March 15, 2027 to regain minimum $2.5M equity
- Proposed merger with Mentari Therapeutics shareholder vote scheduled for November 4, 2026
Financial Impact
Cash burn of $1.1M in the quarter; negative equity of $1.2M; cash runway of approximately 2 weeks from filing date
Risk Factors
- Cash runway only into mid-November 2026, creating existential risk if merger does not close
- Negative shareholders' equity of $1.2M with Nasdaq minimum equity requirement of $2.5M
- Merger with Mentari may not receive required shareholder approval
- No revenue stream; continued operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062993-26-005723 |
| Document: form8k.htm | 0001062993-26-005723 |
| Document: 0001062993-26-005723-index-headers.html | 0001062993-26-005723 |
| Document: 0001062993-26-005723-index.html | 0001062993-26-005723 |
| Document: 0001062993-26-005723.txt | 0001062993-26-005723 |
Track record
22 reports on INM
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +19.19% at T+5 after the Mar 20, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Viewing Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers